OBJECTIVE: In response to post-Women's Health Initiative dialog regarding individualized hormone replacement therapy (HRT), this study evaluates cardiovascular and neuroendocrine effects of HRT versus placebo in postmenopausal women grouped according to time since menopause. STUDY DESIGN:Resting and stress blood pressure (BP), hemodynamic, plasma catecholamine, andcholesterol levels were obtained in 69 women randomly assigned toplacebo or active HRT in a 6-month double-blind study. Analyses evaluated if treatment effects differed among those postmenopausal less than 5 years versus 5 years or more. RESULTS: Compared with the placebo-treated and HRT > or =5 groups, the HRT < 5 group showed reduced BP (P<.0007) and trends toward reduced vascular resistance and norepinephrine (P<.07). HRT > or =5 group generally did not differ from placebo. CONCLUSION: Reduced BP and sympathetic tone are evident in some HRT users, with diminishing benefit after the initial postmenopausal years. Time since menopause may be an important consideration in making individualized patient treatment decisions.
RCT Entities:
OBJECTIVE: In response to post-Women's Health Initiative dialog regarding individualized hormone replacement therapy (HRT), this study evaluates cardiovascular and neuroendocrine effects of HRT versus placebo in postmenopausal women grouped according to time since menopause. STUDY DESIGN: Resting and stress blood pressure (BP), hemodynamic, plasma catecholamine, and cholesterol levels were obtained in 69 women randomly assigned to placebo or active HRT in a 6-month double-blind study. Analyses evaluated if treatment effects differed among those postmenopausal less than 5 years versus 5 years or more. RESULTS: Compared with the placebo-treated and HRT > or =5 groups, the HRT < 5 group showed reduced BP (P<.0007) and trends toward reduced vascular resistance and norepinephrine (P<.07). HRT > or =5 group generally did not differ from placebo. CONCLUSION: Reduced BP and sympathetic tone are evident in some HRT users, with diminishing benefit after the initial postmenopausal years. Time since menopause may be an important consideration in making individualized patient treatment decisions.
Authors: John T Clark; Munmun Chakraborty-Chatterjee; Milton Hamblin; J Michael Wyss; Ian H Fentie Journal: Endocrine Date: 2004-11 Impact factor: 3.633
Authors: C Noel Bairey Merz; B Delia Johnson; Sarah L Berga; Glenn D Braunstein; Ricardo Azziz; Yuching Yang; Steven E Reis; Vera Bittner; T Keta Hodgson; Carl J Pepine; Barry L Sharaf; George Sopko; Sheryl F Kelsey Journal: J Womens Health (Larchmt) Date: 2009-09 Impact factor: 2.681
Authors: Debra A Heller; Carol H Gold; Frank M Ahern; Kristine E Pringle; Theresa V Brown; Margaret R Glessner Journal: BMC Womens Health Date: 2005-05-16 Impact factor: 2.809